Recent Developments in Alzheimer's Disease Therapeutics
Author Information
Author(s): Michael S Rafii, Paul S Aisen
Primary Institution: University of California San Diego
Hypothesis
The review discusses the current status of Alzheimer's disease therapies under study and the scientific context in which they have been developed.
Conclusion
Numerous candidate disease-modifying therapies that target the underlying pathogenic mechanisms of Alzheimer's disease are currently in clinical trials.
Supporting Evidence
- Alzheimer's disease affects more than 37 million people worldwide.
- Current FDA-approved drugs provide only modest symptomatic benefits.
- The number of agents in development for Alzheimer's disease has increased dramatically.
Takeaway
Scientists are trying to find new medicines to help people with Alzheimer's disease by targeting the harmful proteins in the brain.
Methodology
The review summarizes various therapeutic strategies and clinical trials related to Alzheimer's disease.
Limitations
The review does not provide specific limitations but notes that predicting the success of individual programs is challenging.
Participant Demographics
Patients with mild to moderate Alzheimer's disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website